Valuation: Ovid Therapeutics Inc.

Market Cap 491M 425M 397M 363M 684M 46.82B 695M 4.66B 1.83B 23.42B 1.84B 1.8B 78B P/E 2026 *
-5.45x
P/E 2027 * -5.01x
Enterprise Value 491M 425M 397M 363M 684M 46.82B 695M 4.66B 1.83B 23.42B 1.84B 1.8B 78B EV / Sales 2026 *
4,566x
EV / Sales 2027 * 2,945x
Free-Float
92.96%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day-2.47%
1 week+10.09%
Current month+15.54%
1 month+1.79%
3 months-8.06%
6 months+56.40%
Current year+57.36%
1 week 2.33
Extreme 2.33
2.69
1 month 2.2
Extreme 2.2
2.69
Current year 1.36
Extreme 1.36
3.1
1 year 0.52
Extreme 0.5194
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.2
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 31/12/2025
Director of Finance/CFO 59 05/07/2026
Chief Tech/Sci/R&D Officer 60 01/12/2025
Director TitleAgeSince
Chairman 72 31/03/2014
Director/Board Member 81 22/11/2015
Director/Board Member 61 13/06/2017
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Free

Chief Financial Officer

50,000 0.0268%
06/07/26 Other

Chief Financial Officer

450,625 0.2414%
07/04/26 Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
-2.85%+10.09%+361.58%-27.13% 491M
+4.21%+25.62%+77.96%+111.62% 68.12B
+0.50%+6.20%+38.65%+67.83% 55.18B
+1.42%+35.25%+17.95%+486.05% 28.63B
+0.57%+19.05%+57.08%+5.18% 23.99B
-0.67%+1.08%-14.65%-11.58% 23.53B
-0.35%+7.91%+46.74%-22.61% 18.45B
-2.04%+9.24%+31.14%+650.71% 16.44B
+7.26%+25.47%+221.03%+383.67% 15.83B
-2.09%-4.40%+40.70%+148.87% 13.4B
Average +0.64%+12.03%+87.82%+179.26% 26.41B
Weighted average by Cap. +1.54%+11.65%+55.21%+164.54%

Financials

2026 *2027 *
Net sales 108K 93.06K 86.99K 79.5K 150K 10.25M 152K 1.02M 400K 5.13M 404K 395K 17.08M 167K 144K 135K 123K 232K 15.9M 236K 1.58M 621K 7.95M 626K 612K 26.49M
Net income -77.12M -66.76M -62.4M -57.03M -107M -7.36B -109M -732M -287M -3.68B -290M -283M -12.26B -89.58M -77.55M -72.48M -66.25M -125M -8.54B -127M -850M -334M -4.27B -336M -329M -14.24B
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
10/08/26 US$2.540 -3.42% 457,386
07/08/26 US$2.630 -0.75% 919,698
06/08/26 US$2.650 +1.15% 1,294,431
05/08/26 US$2.620 +3.15% 2,253,578
04/08/26 US$2.540 +9.01% 1,666,461
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.630USD
Average target price
5.693USD
Spread / Average Target
+116.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock